Stay updated on Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.

Latest updates to the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a clinical trial for abrocitinib and the addition of a new version revision and helpful links provided by Pfizer.SummaryDifference6%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.